	US 12,187,803 B2
	Bispecific antibody that binds to CD116 and CD131
Akifumi Kato, Tokyo (JP); Harue Nishiya, Tokyo (JP); Ryosuke Nakano, Tokyo (JP); and Toshimasa Harumoto, Tokyo (JP)
Assigned to KYOWA KIRIN CO., LTD., Tokyo (JP)
Filed by KYOWA KIRIN CO., LTD., Tokyo (JP)
Filed on Feb. 26, 2024, as Appl. No. 18/587,502.
Application 18/587,502 is a continuation of application No. PCT/JP2022/032233, filed on Aug. 26, 2022.
Claims priority of application No. 2021-138181 (JP), filed on Aug. 26, 2021.
Prior Publication US 2024/0190980 A1, Jun. 13, 2024
Int. Cl. C07K 16/28 (2006.01); C12N 5/10 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01)

CPC C07K 16/2866 (2013.01) [C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01)]

14 Claims

1. A bispecific antibody or a bispecific antibody fragment thereof comprising:

a first antigen-binding domain; and

a second antigen-binding domain, wherein

the first antigen-binding domain is an antigen-binding domain binding to CD131, and the second antigen-binding domain is an antigen-binding domain binding to CD116, and

the first antigen-binding domain comprises a heavy chain variable region (VH) comprising CDRs 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs: 85 to 87, respectively, and a light chain variable region (VL) comprising CDRs 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs: 88 to 90, respectively, and the second antigen-binding domain comprises a VH comprising CDRs 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs: 137 to 139, respectively, and a VL comprising CDRs 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs: 88 to 90, respectively.